German drugmaker Boehringer Ingleheim has reported on its pipeline at its second international R&D press conference, unveiling three unique oral anti-diabetic compounds in Phase II and III and so entering the diabetes sector for the first time.
"Our research into new treatment options for patients with type 2 diabetes began in 2001 and is now bearing fruit. This is particularly important since, despite a variety of treatment options available today, patients continue to struggle with tolerability," said Klaus Dugi, vice president of medical affairs.
Three new diabetes candidates in Phase II/III
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze